Drug intelligence / Profile preview

VG-290131

Development stage: Phase 1
Lead developer: Zhejiang Vimgreen Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

VG-290131 is an investigational small molecule drug developed by Zhejiang Vimgreen Pharmaceuticals for the treatment of nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). The drug acts as an agonist of the adenosine A3 receptor and is administered orally. As of late 2023, it is in Phase I clinical trials in Australia. The mechanism involves modulation of adenosine signaling pathways, which are implicated in various physiological processes including metabolism.

Targets

ADORA3 (Adenosine A3 receptor)

Beyond the preview

Go deeper on VG-290131.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VG-290131.

Explore the full profile